Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients

Next Previous
X
Search
Trial Profile

A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pruxelutamide (Primary)
  • Indications COVID 2019 infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Suzhou Kintor Pharmaceuticals

    • Most Recent Events

    • 14 Aug 2023 Status changed from recruiting to discontinued.
    • 25 Mar 2022 According to a Kintor Pharma media release, the company expects to release interim analysis data in H2 2022.
    • 11 Feb 2022 According to a Kintor Pharmaceutical Limited media release, the sites that participate in this trial in China include Beijing Ditan Hospital, China-Japan Friendship Hospital, the Third People's Hospital of Shenzhen, Shanghai Public Health Clinical Center, Hangzhou Xixi Hospital, the Public Health Clinical Center of Chengdu and the Fifth People's Hospital of Suzhou.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top